Navigation Links
GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act'

Hails Legislation as Pro-Patient and Pro-Pharmaceutical Innovation

ARLINGTON, Va., March 11 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger regarding the introduction of H.R. 1427, the Bipartisan Biogenerics Consensus Bill: "Promoting Innovation and Access to Life-Saving Medicine Act."

"For the countless patients who are unable to afford the biopharmaceutical medicines they desperately need, today's bipartisan introduction of the 'Promoting Access to Life-Saving Medicine Act' provides great hope that they will soon be able to obtain high quality care at more affordable costs. We applaud Chairman Henry Waxman (D-CA) and Rep. Nathan Deal (R-GA), Rep. Frank Pallone (D-NJ) and Rep. Jo Ann Emerson (R-MO) for working together to introduce this consensus bill that achieves the balance of fostering pharmaceutical innovation while also making affordable medicines available to consumers. And we look forward to the bipartisan introduction of a companion bill in the Senate in the near future.

"As our nation acts to strengthen our health care system, our priority must be to reduce costs while increasing access to quality care. Studies continue to show that creating a workable biogenerics approval pathway will not only bring life-saving medicines to patients in need, it will also save our health care system billions of dollars.

"That's why consumer, business and labor organizations, AARP and many of our nation's governors support legislation that brings biogeneric medicines to consumers sooner rather than later through timely resolution of patent disputes and market exclusivity provisions consistent with the Hatch-Waxman model. Over the past two years, members of Congress have learned a great deal about biogenerics. They've heard from the FDA that the science exists to approve safe, effective and affordable biogenerics. They've heard that the FDA scientists want the authority and flexibility to determine how to best ensure safety and efficacy. And they've heard that significant cost savings will result from bringing biogenerics to consumers.

"This bipartisan bill recognizes our health care system's successful experience with generic medicines for the past 25 years. The market exclusivity provisions in Hatch-Waxman have clearly demonstrated that we can achieve the much-needed balance between pharmaceutical competition and innovation for the benefit of consumers, payors and state and federal governments. We've done it before with generics and we can do it again with biogenerics.

"Now, it's time for action. Now, more than ever, it's time to put patients first.

"During these difficult economic times, there must be increased urgency to support solutions that strengthen health care while reducing costs. 'The Promoting Innovation and Access to Life-Saving Medicine Act' is the right solution for high quality care at affordable costs."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information on biogenerics, please log on to

SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CV Therapeutics Statement on Unsolicited Proposal From Astellas
2. Sinovac Releases Statement on Healive Vaccine Suspension
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
5. Resverlogix Issues a Management Statement
6. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
7. Jazz Pharmaceuticals Files Form S-3 Registration Statements
8. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
9. Statement from Lighthouse International About the Study on Gene Therapy Concerning Lebers Congenital Amaurosis
10. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
11. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would ... named to Deloitte's 2015 Technology Fast 500 list of the fastest growing companies ... FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by as ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/24/2015)... ... ... Whitehouse Laboratories is pleased to announce that it has completed construction on ... to basic USP 61, USP 62 and USP 51 testing specific to raw materials ... micro testing performed by one supplier. Management has formally announced that the ...
(Date:11/23/2015)...   Ceres, Inc . (Nasdaq: CERE ), ... the fiscal year ended August 31, 2015 and provided ... --> During fiscal year 2015, Ceres ... with a better balance of yield, energy and nutrition. ... several leading crop input providers and made significant progress ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
Breaking Biology News(10 mins):